MedTrace Logo

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

NCT03029351 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-04-16

Study results available
· View outcomes & findings →

Summary

This is a prospective study to evaluate effect of Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.

Conditions

Interventions

DRUG

Exenatide Extended Release for Inj Susp 2 MG

Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria

DRUG

Placebo

placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University at Buffalo

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-10
Primary Completion
2019-07-31
Completion
2019-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03029351 on ClinicalTrials.gov